| Document |
Document Title |
|
WO/2012/047495 |
This invention relates generally to methods for preparing certain bile acids from non-mammalian sourced starting materials as well as to synthetic bile acids and compositions comprising such acids wherein the acids are characterized by a...
|
|
WO/2011/157443 |
The present invention relates to (11β,17α)-11-(4-(2-11C-acetyl)phenyl)-17,23- epoxy-19,24-dinorchola-4,9,20-trien-3-one, an 11C-labelled ORG 33628; a process for the preparation thereof, intermediates used in this process and the use o...
|
|
WO/2011/075701 |
Synthetic methods for preparing deoxycholic acid and intermediates thereof, high purity synthetic deoxycholic acid, compositions and methods of use are provided. Also, provided are processes for the synthesis of 12-keto or 12-α-hydroxys...
|
|
WO/2010/118560 |
The invention provides a process for preparing eplerenone, which comprises the following steps: (1) in the presence of a side reaction inhibitor, 17α-hydroxyl-3-oxo-γ-lactone-pregn-4,9(11)-diene-7α,21-di
carboxylic acid methyl ester I...
|
|
WO/2010/118023 |
Described herein are methods of making drospirenone. Also described are intermediate compounds that may be used to synthesis drospirenone.
|
|
WO/2010/118025 |
Described herein are compounds which exhibit progesterone antagonistic effects and methods of treating cancer using such compounds.
|
|
WO/2010/000070 |
The present invention relates to a process for extracting, purifying and isolating cyclopamine from cyclopamine-containing biomass comprising the steps of contacting cyclopamine-containing organic matter with an extractant (e.g., aqueous...
|
|
WO/2009/124460 |
The invention discloses Tripterygium wilfordii diterpene lactone derivatives represented by formula (1), their optical isomers and pharmaceutically acceptable salts and hydrates. The invention also provides pharmaceutical compositions an...
|
|
WO/2009/083268 |
The invention relates to 17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-one derivatives with general chemical formula (1) wherein the radicals Z, R4, R6a, R6b, R7, R15, R16a, R16b and R18 have the designations given in claim 1, and to the solv...
|
|
WO/2009/083268 |
The invention relates to 17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-one derivatives with general chemical formula (1) wherein the radicals Z, R4, R6a, R6b, R7, R15, R16a, R16b and R18 have the designations given in claim 1, and to the solv...
|
|
WO/2009/004394 |
The present invention relates to a novel selective synthesis of 9α-hydroxy-steroid derivatives of the general formula (I) (I) - wherein the meaning of -A-A'- is -CH2-CH2- or -CH=CH- group - by the bioconversion of compounds of the gener...
|
|
WO/2009/004394 |
The present invention relates to a novel selective synthesis of 9α-hydroxy-steroid derivatives of the general formula (I) (I) - wherein the meaning of -A-A'- is -CH2-CH2- or -CH=CH- group - by the bioconversion of compounds of the gener...
|
|
WO/2009/004394 |
The present invention relates to a novel selective synthesis of 9α-hydroxy-steroid derivatives of the general formula (I) (I) - wherein the meaning of -A-A'- is -CH2-CH2- or -CH=CH- group - by the bioconversion of compounds of the gener...
|
|
WO/2009/001148 |
The present invention relates to a process for the synthesis of the known 17-acetoxy-11-β-[4-(dimethylamino)-phenyl]-21-methoxy-19-no
rpregna-4,9-dien-3,20-dione (further on CDB-4124) of formula (I) from 3,3-[1,2-etandiyl-bis(oxy)]-oest...
|
|
WO/2009/001148 |
The present invention relates to a process for the synthesis of the known 17-acetoxy-11-β-[4-(dimethylamino)-phenyl]-21-methoxy-19-no
rpregna-4,9-dien-3,20-dione (further on CDB-4124) of formula (I) from 3,3-[1,2-etandiyl-bis(oxy)]-oest...
|
|
WO/2008/155534 |
The present invention relates to novel neurosteroid derivatives with anti-apoptotic, neuroprotective and neurogenic properties that act on the nervous system as well as methods for making the same and their applications in the treatment ...
|
|
WO/2008/155534 |
The present invention relates to novel neurosteroid derivatives with anti-apoptotic, neuroprotective and neurogenic properties that act on the nervous system as well as methods for making the same and their applications in the treatment ...
|
|
WO/2008/155534 |
The present invention relates to novel neurosteroid derivatives with anti-apoptotic, neuroprotective and neurogenic properties that act on the nervous system as well as methods for making the same and their applications in the treatment ...
|
|
WO/2008/067086 |
The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating estrogen-dependent conditions such as endometrial hyper...
|
|
WO/2008/058767 |
The present invention relates to progesterone receptor antagonists of general formula I: in which R1 can be a hydrogen atom and R2 a hydroxyl group or R1 and R2 together can be an oxo group.
|
|
WO/2008/011005 |
Compositions and methods for treating mammalian diseases or conditions characterized by abnormal cell mitosis and/or abnormal or undesirable angiogenesis, by administering an effective amount of analogs of 2-methoxyestradiol. Compounds t...
|
|
WO/2008/011005 |
Compositions and methods for treating mammalian diseases or conditions characterized by abnormal cell mitosis and/or abnormal or undesirable angiogenesis, by administering an effective amount of analogs of 2-methoxyestradiol. Compounds t...
|
|
WO/2007/144674 |
The present invention relates to a new industrial process for the synthesis of solvate- free 17α-acetoxy-11β-[4-(N,N-dimethyl-amino)-phenyl]-19-norpreg
na-4,9-diene-3,20-dione [CDB -2914] of formula (I) which is a strong antiprogestoge...
|
|
WO/2007/118717 |
The present invention relates to a method for the reliable and reproducible preparation of 4-[17β-methoxy-17α-methoxymethyl-3-oxoestra-4,9-dien-llβ-
yl]benzaldehyde (E)-oxime (asoprisnil) on the pilot and manufacturing scale. Asopris...
|
|
WO/2007/118717 |
The present invention relates to a method for the reliable and reproducible preparation of 4-[17β-methoxy-17α-methoxymethyl-3-oxoestra-4,9-dien-llβ-
yl]benzaldehyde (E)-oxime (asoprisnil) on the pilot and manufacturing scale. Asopris...
|
|
WO/2007/025780 |
Compounds of the formula (I), (R1 is one of a wide range of substituents; R2 = H, halogen and R3 = H, hydroxymethyl or CR2R3 = cyclopropyl ring; CR4R5 is one of formula (II), formula (III) and formula (IV) Ra and Rb are a bond between ca...
|
|
WO/2007/025780 |
Compounds of the formula (I), (R1 is one of a wide range of substituents; R2 = H, halogen and R3 = H, hydroxymethyl or CR2R3 = cyclopropyl ring; CR4R5 is one of formula (II), formula (III) and formula (IV) Ra and Rb are a bond between ca...
|
|
WO/2007/004090 |
The present invention relates to processes for the prepartion of purified solanesol, solanesyl bromide & solanesyl acetone. Solanesyl acetone has the chemical name - all - trans 6, 10, 14, 18, 22, 26, 30, 34, 38 -nonamethyl -5,9, 13, 17,...
|
|
WO/2006/062129 |
A process for producing (5&agr ,7&agr )-3-spiro-2'-(1',3'-dioxolan)-24-oxocholest-22-en-7-yl benzoate (unsaturated ketone (I)), which is represented by the formula (I), (I) characterized by dissolving in methanol a crude reaction product...
|
|
WO/2006/052263 |
Methods for separation and synthesis of the optically active 7-thioester isomers and mono or bis-cyclopropyl derivatives of spironolactone are provided. Preferred stereoisomerically purified 7-thioester isomers and mono or bis-cyclopropy...
|
|
WO/2006/045745 |
A process is described for preparing, exclusively by chemical way, 21-hydroxy steroids having progestinic activity, said process having a high stereochemical control at C-21 position.
|
|
WO/2006/032970 |
Processes are described for the conversion of a steroid substrate having a 4,7-carbonyl bridge to a structure comprising a 7&agr -alkoxycarbonyl substituent by reaction of the substrate with an alkoxy group source, preferably in the pres...
|
|
WO/2005/000865 |
A microbial method for hydrolysis and oxidation of androst-5-ene and pregn-5-ene steroid esters is disclosed.
|
|
WO/2004/089304 |
The instant invention provides potent antiandrogen compounds, such as 3β -acetoxyandrost-1,5-diene-17-ethylene ketal and 3β-hydroxyandrost-1, 5-diene-17ethylene ketal, and methods for their use in the prevention and treatment of biolog...
|
|
WO/2004/078709 |
Methods for the preparation of the 19-norprogesterone of formula I and its intermediates, in crystalline and amorphous forms.
|
|
WO/2004/043987 |
This invention relates to processes for the preparation of 7-carboxy substituted steroid compounds of Formula (I) wherein R1 is selected from H or COR4; R4 is C1-C6 alkyl or C1-C6 alkoxy; R3 is C1-C6 alkyl; Z1 is -CH2- or Formula (II) wh...
|
|
WO/2004/043986 |
This invention relates to processes for the preparation of novel , substituted steroid compounds of Formula 1, wherein R1 is H or. COR2; R2 is C1-C6 alkyl or Ct-C6 alkoxy; Z1 is CH2, or wherein OR3 is in the &agr configuration; R3 is H o...
|
|
WO/2004/037843 |
The present invention relates to multifunctional steroid compounds combining a steroid component with SOD mimic component and optionally also with NO donor component, and to their use in treating and preventing disorders associated with ...
|
|
WO/2004/037844 |
The present invention involves a novel crystal form of 17β-hydroxy-7&agr -(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxyli
c acid, &gammad -lactone (II) which is an intermediate useful in preparation of an important pharmaceu...
|
|
WO/2004/031204 |
The present invention is a process for the preparation of l7ß-hydroxy-7&agr -methyl-19-nor-17&agr -pregn-5(10)-en-20-yn-3-one (17&agr -ethynyl-l7ß-hydroxy-7&agr -methyl-5(10)-estren-3-one, tibolone) of formula 1, which comprises hydrol...
|
|
WO/2004/016640 |
The present invention provides 5-androsten-3β-ol steroid intermediates and processes for their preparation.
|
|
WO/2004/014934 |
The present invention relates to a new process of synthesis and to some new intermediates for the preparation of steroids with progestogen activity, more particularly, for the preparation of Desogestrel of formula (I). Said process is ch...
|
|
WO/2004/007370 |
A process for producing a raw material for the formation of proton-exchanged zeolite analogues whose cations are wholly or partially exchanged by H+ and which contain zeolite having tektosilicate structure, characterized by the step of t...
|
|
WO/2004/005310 |
The present invention relates (a) to new compounds represented by Formula (I): wherein M represents a macrolide subunit (macrolide moiety) derived from macrolide possessing the property of accumulation in inflammatory cells, S represents...
|
|
WO/2003/082894 |
Novel processes for the C-17 spirolactonization and 6,7 oxidation of steroid compounds are provided. In certain preferred embodiments, the present invention provides for the preparation of steroid compounds which are useful in the prepar...
|
|
WO/2003/082895 |
The present invention involves novel intermediates, including a 7&agr -substituted steriod (II), and various novel processes which are used to prepare known intermediates useful in the production of eplerenone, a pharmaceutical agent.
|
|
WO/2003/075015 |
The invention relates to a method of screening cellular polypeptides for pro-apoptotic or anti-apoptotic activity in a cell of a particular cell-type, said method comprising a. culturing cells of said particular cell-type under non apopt...
|
|
WO/2003/068736 |
Disclosed herein are mixed steroidal tetraoxanes having the following structural Formula (I), wherein n is 0, 1, 2, or 3; R is H; ethanoyl, propanoyl, or benzoyl; R1 is H, methyl, ethyl, or isopropyl; R2 is H, methyl, or ethyl; R3 is H, ...
|
|
WO/2003/006027 |
A pharmaceutical dosage unit comprising drospirenone and an estrogen sulphamate, such as an estradiol sulphamate or an estriol sulphamate for use in hormone replacement therapy is disclosed. This, combination therapy may comprise continu...
|
|
WO/2002/102391 |
The invention relates to nanoparticles comprising spironolactone. The nanoparticles have a mean diameter, measured by photon correlation spectroscopy, in the range of from about 300nm to about 900nm.
|
